The High Potent Market And The Role Of A Specialist CDMO

By Dr Rebecca Coutts, PhD, MBA, General Manager, PCI Pharma Services Tredegar

Originally published by PHARMAnetwork Ltd.

The development and manufacture of drug products containing highly potent active pharmaceutical ingredients (HPAPIs) is in demand. Recent data suggest that between 2023 and 2030, the small molecule drug discovery market will register a compound annual growth rate (CAGR) of around 8%. This is particularly relevant in the field of oncology, which accounts for around 35% percent of small molecule drug candidates, around half of which contain HPAPIs.

Targeted therapies are revolutionizing cancer care, offering hope for safer, more effective treatments. But translating these discoveries into accessible drugs requires a delicate balance of speed, safety, and expertise. Safe handling of highly potent molecules is complex, and the associated regulatory requirements are growing.

Outsourcing the development and manufacturing of drugs with HPAPIs to an experienced, reliable CDMO partner is emerging as a beneficial method to optimize resources, leverage expertise, de-risk investment, and accelerate drug development timelines. However, to ensure success, sponsor companies must conduct due diligence to identify truly specialist CDMOs that offer safe, regulatory-compliant, scalable, and flexible processes as well as end-to-end solutions to support the entire drug lifecycle. Discover how biopharmaceutical companies can leverage CDMO expertise to ensure their life-saving cancer treatments reach patients faster, safely, and cost-effectively.

Reprinting with PHARMAnetwork Ltd - Copyright 2023/2024 All rights reserved www.pharmanetwork.digital.